Sun Pharma Q4 2026 Results: PAT Rises 26%YoY, Announced ₹5 Dividend
Sun Pharma reported double-digit revenue growth in Q4 FY26, driven by India formulations and emerging markets business, while net profit rose 26% YoY.
Quick Summary
Sun Pharma Q4 2026 Results: Sun Pharmaceutical Industries reported consolidated revenue from operations of ₹14,611.79 crore in Q4 FY26, up ~13% YoY. Consolidated net profit rose 26.24% YoY to ₹2,714.03 crore, while the company announced a final dividend of ₹5 per share.
Sun Pharma Q4 2026 Results: Sun Pharmaceutical Industries on 22 May 2026 reported its consolidated financial results for the quarter ended 31 March 2026. Net profit for the period jumped 26% YoY, supported by all segments
Sun Pharma Q4 2026 Results Highlights (Consolidated)
Sun Pharma posted double-digit revenue growth during the quarter, supported by strong India formulations performance and growth in innovative medicines business
|
Metric |
Q4 FY26 |
Q3 FY26 |
QoQ % |
Q4 FY25 |
YoY % |
|
Revenue from Ops (₹ Cr) |
14,611.79 |
15,520.54 |
-5.85% |
12,958.84 |
+12.75% |
|
Total Income (₹ Cr) |
15,070.29 |
16,099.38 |
-6.39% |
13,571.71 |
+11.04% |
|
EBITDA (₹ Cr) |
3,954.20 |
4,948.49 |
-20.09% |
3,716.09 |
+6.41% |
|
EBITDA Margin % |
27.1% |
31.9% |
-480 bps |
28.7% |
-160 bps |
|
Net Profit (₹ Cr) |
2,714.03 |
3,368.81 |
-19.43% |
2,149.88 |
+26.24% |
Source: Company filing
-
Consolidated revenue from operations stood at ₹14,611.79 crore in Q4 FY26 compared with ₹12,958 crore in Q4 FY25, registering a growth of 12.75% year-on-year. Revenue declined 5.85% from Q3 FY26.
-
Total income came in at ₹15,070.29 crore in Q4 FY26 against ₹16,099.38 crore in Q3 FY26, down 6.39% QoQ, but JUmp 11%YoY
-
Consolidated profit after tax stood at ₹2,714.03 crore in Q4 FY26 compared with ₹2,149.90 crore in Q4 FY25, reflecting a rise of 26.24% YoY. PAT declined 19.43% from Q3 FY26.
Sun Pharma Segment Wise Sales
Sun Pharma said India formulations sales rose 14.8% YoY to ₹4,835.89 crore during the quarter and accounted for 33.2% of total consolidated sales.
|
Segment |
Q4 FY26 (₹ Cr) |
Q4 FY25 (₹ Cr) |
YoY% |
|
India Formulations |
4,835.89 |
4,212.96 |
14.79% |
|
US Formulations |
4,199.71 |
4,020.41 |
4.46% |
|
EM Formulations |
2,797.05 |
2,256.12 |
23.98% |
|
ROW Formulations |
2,013.97 |
1,733.97 |
16.15% |
|
API |
713.13 |
592.12 |
+20.4% |
|
Total Sales |
14,559.75 |
12,815.58 |
+13.6% |
Sun Pharma Full-Year Performance Remained Strong
Sun Pharma reported healthy growth in consolidated revenue and operating cash flow during FY26.
|
Metric |
FY26 |
FY25 |
YoY Change |
|
Consolidated Revenue (₹ Cr) |
58,462.04 |
52,578.44 |
+11.19% |
|
Consolidated Net Profit (₹ Cr) |
11,479.42 |
10,929.04 |
+5.04% |
|
Operating Cash Flow (₹ Cr) |
12,419.18 |
14,072.09 |
-11.75% |
Source: NSE filing, Sun Pharmaceutical Industries FY26 Consolidated Annual Results
Sun Pharma Dividend and Stock Price Today
The Board recommended a final dividend of ₹5 per share for FY26 on a face value of Re 1 each. Earlier, the company had already announced an interim dividend of ₹11 per share, taking the total dividend for FY26 to ₹16 per share, unchanged from last year.
As of 22 May, 3.30 PM
Since morning of 22 May, Sun Pharma shares remained under pressure and closed 2.71% lower compared to Thursday’s closing price. On a year-to-date basis and over the one-year period from 22 May 2025 to 22 May 2026, Sun Pharma stock has gained around 7%.